Related Experiment Video

Updated: Aug 12, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Hepatitis B

Kenneth W Lin1, Jeffrey T Kirchner

  • 1Department of Family and Community Medicine, Lancaster General Hospital, Lancaster, Pennsylvania 17604, USA.

American Family Physician
|January 20, 2004
PubMed

Insights

Hepatitis B affects over 400 million globally, causing significant deaths from liver cancer. Vaccination has reduced new infections, but chronic hepatitis B requires ongoing medical therapies.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis B virus (HBV) infection poses a substantial global health burden, leading to widespread morbidity and mortality.
  • Over 400 million individuals worldwide, including 1.25 million in the U.S., live with chronic hepatitis B.
  • Chronic HBV infection is a leading cause of cirrhosis and hepatocellular carcinoma (liver cancer) in the United States, accounting for approximately 5,000 deaths annually.

Purpose of the Study:

  • To summarize the epidemiology, transmission, prevention, and treatment of Hepatitis B.
  • To highlight the impact of vaccination programs on new Hepatitis B infections.
  • To outline current medical therapies for chronic Hepatitis B.

Main Methods:

  • Review of epidemiological data on Hepatitis B prevalence and mortality.
  • Analysis of transmission routes, including sexual contact, intravenous drug use, occupational, and perinatal exposure.
  • Summary of the efficacy of Hepatitis B vaccines and the impact of vaccination programs.
  • Overview of risk factors for progression to chronic infection.
  • Compilation of available medical therapies for chronic Hepatitis B.

Main Results:

  • Hepatitis B causes significant global morbidity and mortality, with over 400 million chronically infected individuals worldwide.
  • Vaccination programs, particularly since the 1990s, have led to a marked reduction in new Hepatitis B infections in the U.S.
  • Key risk factors for chronicity include age at infection and immune status, with 15-30% of acute cases progressing to chronic infection.
  • Established medical therapies for chronic Hepatitis B include interferon alfa-2b, lamivudine, and adefovir dipivoxil.

Conclusions:

  • Hepatitis B remains a critical global health concern requiring continued prevention and management strategies.
  • While vaccination has been highly effective in reducing incidence, a significant population remains at risk for severe outcomes like liver cancer.
  • Effective medical treatments are available for chronic Hepatitis B, targeting viral suppression and disease progression.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...